Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
1 finding from 1 review
Resolution of daytime urinary incontinence · children aged 5 to 16 years with daytime urinary incontinence
Voiding education with uroflow feedback and urotherapy showed no clear difference in resolution of daytime urinary incontinence at 6 to 12 months after 6… compared with urotherapy alone (low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective measurement of volume of incontinent episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 5 to 16 years with daytime urinary incontinence
1 finding from 1 review
MWD ‐ change from baseline · people with symptomatic peripheral arterial disease§
1 finding from 1 review
Change from baseline in 6MWT (metres) · people with symptomatic peripheral arterial disease§
1 finding from 1 review
PFWD (change in metres) (4–40 weeks' · people with symptomatic peripheral arterial disease§
1 finding from 1 review
ABI ‐ absolute value · people with symptomatic peripheral arterial disease§
1 finding from 1 review
All‐cause mortality · people with symptomatic peripheral arterial disease§
It is very uncertain whether supervised exercise therapy following vascular intervention changes mortality compared with vascular intervention alone (very low certainty).
1 finding from 1 review
Quality of Life: SF‐36 (physical component) · people with symptomatic peripheral arterial disease§
1 finding from 1 review
Reintervention · people with symptomatic peripheral arterial disease§
It is very uncertain whether supervised exercise therapy following vascular intervention changes reintervention compared with vascular intervention alone (very low certainty).
1 finding from 1 review
Fluorosis (percentage prevalence in permanent teeth) · Children exposed to topical fluoride when under 6 years old; fluorosis assessed in permanent teeth at 6 to 18 years
It is very uncertain whether fluoride toothpaste less than 1000 ppm (lower concentration) changes fluorosis (percentage prevalence in permanent teeth) compared with fluoride toothpaste 1000 ppm or more (higher concentration) (very low certainty).
2 findings from 1 review
Canine expansion · Children and adults with a posterior crossbite, without a Class III skeletal relationship, cleft lip or palate (or both), or other…
Fixed bonded Hyrax appliance followed by U-bow activator therapy showed no clear difference in canine expansion compared with no treatment; GRADE not reported.
1 finding from 1 review
Molar expansion · Children and adults with a posterior crossbite, without a Class III skeletal relationship, cleft lip or palate (or both), or other…
Fixed bonded Hyrax appliance followed by U-bow activator therapy showed no clear difference in molar expansion compared with no treatment; GRADE not reported.
1 finding from 1 review
Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Overall survival (OS) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review